Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are medications that help to relax the muscles in the airways, making it easier to breathe. In Iraq, the market for bronchodilator drugs has been experiencing steady growth in recent years.
Customer preferences: Customers in Iraq have been increasingly seeking out bronchodilator drugs as a means of managing respiratory illnesses such as asthma and chronic obstructive pulmonary disease (COPD). This is in part due to the high levels of air pollution in many Iraqi cities, which can exacerbate these conditions. Additionally, the aging population in Iraq has also contributed to the growing demand for bronchodilator drugs.
Trends in the market: One of the key trends in the bronchodilator drugs market in Iraq is the increasing availability of generic versions of these medications. This has helped to drive down prices and make these drugs more accessible to a wider range of patients. Additionally, there has been a shift towards the use of combination bronchodilator drugs, which can be more effective than single-agent therapies in managing respiratory conditions.
Local special circumstances: The ongoing conflict in Iraq has had a significant impact on the healthcare system in the country, including the availability of medications. However, despite these challenges, the market for bronchodilator drugs has continued to grow. This is in part due to the fact that respiratory illnesses are a major health concern in Iraq, and many patients are willing to pay for these medications out of pocket if necessary.
Underlying macroeconomic factors: The Iraqi economy has been experiencing a period of instability in recent years, with ongoing conflict and political unrest contributing to a challenging business environment. However, despite these challenges, the healthcare sector in Iraq has remained relatively resilient. This is in part due to the fact that healthcare is a basic human need, and patients are often willing to prioritize spending on healthcare even in difficult economic times. Additionally, the growing demand for bronchodilator drugs in Iraq has created opportunities for pharmaceutical companies to expand their operations in the country.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
